肠肺轴:莫克西布施对喘大鼠各种组织中短链脂肪酸的影响
Yitian Lai1, Jingying Zhou1, Ling Ren1
1Hunan University of Chinese Medicine, College of Acupuncture, Tuina and Rehabilitation, Changsha 410208, China.
International immunopharmacology
|December 19, 2025
概括
在老鼠的喘中,催化剂治疗有效地增加了身体各个区域的短链脂肪酸 (SCFA),减少了呼吸道炎症,并支持了肠肺轴理论. 这突显了SCFA在缓解喘方面的作用.
科学领域:
- 综合医学是一个整体的医学.
- 肺部病理学 肺部病理学
- 微生物组研究 微生物组研究
背景情况:
- 之前的研究证实,moxibustion增强了喘大鼠的肠道短链脂肪酸 (SCFA),支持肠肺轴理论.
- 喘的特征是呼吸道炎症,可能受到肠道微生物群和SCFA水平的影响.
研究的目的:
- 通过增加多个身体区域的SCFA水平,调查moxibustion是否可以控制喘相关的呼吸道炎症.
- 为了比较单独使用"Feishu" (BL13) 和联合使用"Feishu-Tianshu" (BL13-ST25) 治疗的治疗效果.
- 探索莫克西布斯对喘影响的潜在机制.
主要方法:
- 在使用卵胺 (OVA) 的斯普拉格-道利大鼠中建立了一个喘模型.
- 鼠每天在"Feishu" (BL13) 或联合"Feishu-Tianshu" (BL13-ST25) 点进行莫克西布施疗,持续14天.
- 测量包括炎症细胞计数 (BALF,血液,骨髓),肺病理 (HE染色),炎症细胞因子/媒介水平 (IL-5,IL-17,IL-33,TSLP) 和SCFA水平 (气色谱-质谱) 在便,血清,骨髓和肺组织.
主要成果:
- 喘老鼠表现出肺部结构异常,BALF,血液和骨髓中的炎症细胞增加,以及IL-5,IL-17,IL-33和TSLP水平升高.
- 在SCFA水平 (乙,,黄油等) 中. 在便,血清,骨髓和喘老鼠的肺组织中显著减少.
- 与模型组相比,moxibustion治疗 (单点和组合点) 改善了肺病理,减少了炎症标志物,并在所有测量的身体区域显著增加了SCFA水平.
- 联合治疗"Feishu-Tianshu" (BL13-ST25) 与单独治疗"Feishu" (BL13) 相比,在便中酸,黄油酸和六酸水平的显著增加.
结论:
- 大鼠的喘与肠道微生物群的破坏和SCFA水平的降低有关.
- 催化剂有效地增加了肠道,血液,肺组织和骨髓中的SCFA水平,同时减少了呼吸道炎症.
- SCFA可能在减轻喘方面发挥着至关重要的作用,为肠肺轴理论提供了进一步的证据.
相关概念视频
Asthma: Pathogenesis and Management
1.2K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
Antiasthma Drugs: Methylxanthines
1.5K
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
1.5K
Asthma-II: Pathophysiology and Classification
4.0K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.0K
Antiasthma Drugs: Muscarinic Receptor Antagonists
1.6K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.6K
Asthma-I: Introduction
3.3K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.3K


